Across receptor subtypes the median number of lines of treatment was 3 in HR+/HER2− cancers (mean 3.5), also 3 in the HR+/HER2+ group (mean 3.2), 2 in the triple negative group (mean 2.3), and 1 in the HR−/HER2+ group (mean 1.7). This evidence concerns the gene ERBB2 and cancer.